Document is current
Any future updates will be listed below
-
Authors
Wang, Jiali https://orcid.org/0000-0002-9520-8140
Owji, Aaron P.
Kittredge, Alec https://orcid.org/0000-0002-8140-9267
Clark, Zada
Zhang, Yu https://orcid.org/0000-0002-6525-2458
Yang, Tingting https://orcid.org/0000-0002-5220-588X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM149252, R01GM127652)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences
U.S. Department of Health & Human Services | NIH | National Eye Institute (R24EY028758)
Irma T. Hirschl Trust (CU20-4313)
Research to Prevent Blindness (CU22-1892)
- License Information
-
More Information
Article History
Received: 30 October 2023
Accepted: 23 August 2024
First Online: 14 September 2024
Competing interests
: Provisional patents on using GABA analogs (no. 63/591,019) and GAD proteins (63/692,462) as Best1 activators have been filled by Columbia University, listing A.P.O., Y.Z., and T.Y. as inventors for the former and Y.Z. and T.Y. as inventors for the latter. The remaining authors declare no competing interests.
